Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905387 | 0.88 | RECQL (0.39) | MAPTGAARECQLCLK1KMT2A | |
| SCHEMBL2907742 | 0.82 | RECQL (0.53) | MAPTGAARECQLCLK1KMT2A | |
| SCHEMBL2906707 | 0.80 | MAPT (0.46) | MAPTGAARECQLKMT2AMEN1 | |
| SCHEMBL2904980 | 0.79 | EGFR (0.44) | MAPTGAACLK1KMT2AMEN1 | |
| SCHEMBL2905425 | 0.76 | RECQL (0.34) | MAPTGAARECQLCLK1KMT2A | |
| SCHEMBL2906872 | 0.76 | SLC10A2 (0.45) | MAPTRECQLKMT2AMEN1ALDH1A1 | |
| SCHEMBL2906708 | 0.76 | IDO1 (0.42) | MAPTGAARECQLCLK1KMT2A | |
| SCHEMBL2902345 | 0.75 | EPHB4 (0.47) | MAPTGAARECQLCLK1KMT2A | |
| SCHEMBL2906857 | 0.74 | ALDH1A1 (0.38) | MAPTGAARECQLCLK1KMT2A | |
| SCHEMBL2910554 | 0.74 | CLK1 (0.52) | MAPTGAACLK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | claimed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | claimed |
| EP-2076495-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | claimed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | claimed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | claimed |
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-2076495-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | AR, ADRA2C, RCC2 | MAPT 1716/4885GAA 3960/4885RECQL 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.